Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$29 Mln
P/E Ratio
--
P/B Ratio
0.42
Industry P/E
--
Debt to Equity
0
ROE
-0.57 %
ROCE
-56.45 %
Div. Yield
0 %
Book Value
1.21
EPS
-0.93
CFO
$-400.55 Mln
EBITDA
$-421.96 Mln
Net Profit
$-560.96 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
VYNE Therapeutics (VYNE)
| -57.91 | -17.06 | -47.78 | -43.60 | -42.87 | -59.14 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
VYNE Therapeutics (VYNE)
| 43.35 | -13.70 | -85.29 | -83.86 | -65.95 | 12.62 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,904.81 | -- | 38.11 | |
| 73.23 | 7,574.08 | 58.3 | 23.56 | |
| 60.43 | 11,448.88 | 394.4 | 0.76 | |
| 8.34 | 9,704.70 | -- | -3.24 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small... molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Address: 685 Route 202/206 N, Bridgewater, NJ, United States, 08807 Read more
CEO, President & Director
Mr. David T. Domzalski
CEO, President & Director
Mr. David T. Domzalski
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of VYNE Therapeutics Inc (VYNE) stood at $ 67 Mln as on 31-Dec-24
The share price of VYNE Therapeutics Inc (VYNE) is $1.41 (NASDAQ) as of 29-Apr-2025 16:00 EDT. VYNE Therapeutics Inc (VYNE) has given a return of -42.87% in the last 3 years.
VYNE Therapeutics Inc (VYNE) has a market capitalisation of $ 29 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of VYNE Therapeutics Inc (VYNE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the VYNE Therapeutics Inc (VYNE) and enter the required number of quantities and click on buy to purchase the shares of VYNE Therapeutics Inc (VYNE).
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Address: 685 Route 202/206 N, Bridgewater, NJ, United States, 08807
The CEO & director of Mr. David T. Domzalski. is VYNE Therapeutics Inc (VYNE), and CFO & Sr. VP is Mr. David T. Domzalski.
There is no promoter pledging in VYNE Therapeutics Inc (VYNE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| VYNE Therapeutics Inc. (VYNE) | Ratios |
|---|---|
|
Return on equity(%)
|
-56.57
|
|
Operating margin(%)
|
-8709.98
|
|
Net Margin(%)
|
-7950.9
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of VYNE Therapeutics Inc (VYNE) was $0 Mln.
$-0.03
(
